AbbVie (ABBV) Stock Forecast & Price Target

AbbVie is in a strong position with its growing portfolio of immunology drugs, including Humira, Skyrizi, and Rinvoq, and the recent Allergan acquisition has added new offerings in aesthetics. The company also has solid pipeline depth in the neuroscience and oncology verticals, which has the potential to drive future growth beyond its core immunology franchise. This, along with the company's strong governance structure and pricing strategies that balance shareholder value and public health, reinforces my positive outlook on the stock. Additionally, with above-consensus estimates for Skyrizi and the potential for another increase in guidance, I believe that the company's future performance will continue to surpass expectations.

AbbVie is heavily dependent on its immunology and oncology products, with limited diversification from its newer acquisitions in aesthetics, neuroscience, and oncology. The company also faces significant pricing pressures and product liability exposure, which requires robust risk management to sustain shareholder value. Although the company has strong growth drivers in Skyrizi and Rinvoq, there is potential for slower growth and increased competition in these areas.